In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Staying Diversified, Bayer Sees Opportunities In Digital Innovation

Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.

Commercial Digital Health

Japan Cancer Center Looks To Leverage Expertise As It Builds Pharma Ties

Japan's largest cancer center is looking to build on its tissue sample and genomic resources to further build its reputation as a partner facility for the pharma industry's oncology trials. 
Japan Cancer

Novartis Wins Second Landmark German Case, This Time For Probiotics

Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.
Wellness Dietary Supplements

Orphan Drug Access: One-Third Of US Coverage Decisions Involve Restrictions, Study Finds

Tufts researchers report restrictions are more common for orphan drugs indicated for diseases with higher prevalence and that are more expensive.

Reimbursement Pricing Strategies
See All

Company Information

UsernamePublicRestriction

Register